Kodiak Sciences Inc. (KOD) and Rafael Holdings Inc. (NYSEAMERICAN:RFL) Contrasting side by side

Kodiak Sciences Inc. (NASDAQ:KOD) and Rafael Holdings Inc. (NYSEAMERICAN:RFL), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kodiak Sciences Inc. N/A 0.00 40.51M -2.77 0.00
Rafael Holdings Inc. 4.46M 68.54 3.28M -0.06 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 shows Kodiak Sciences Inc. and Rafael Holdings Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Kodiak Sciences Inc. 0.00% 0% 0%
Rafael Holdings Inc. -73.54% -3% -2.7%


18.7 and 18.7 are the respective Current Ratio and a Quick Ratio of Kodiak Sciences Inc. Its rival Rafael Holdings Inc.’s Current and Quick Ratios are 13 and 13 respectively. Kodiak Sciences Inc. has a better chance of clearing its pay short and long-term debts than Rafael Holdings Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Kodiak Sciences Inc. and Rafael Holdings Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kodiak Sciences Inc. 0 0 1 3.00
Rafael Holdings Inc. 0 0 0 0.00

Kodiak Sciences Inc. has a consensus price target of $22.5, and a 87.97% upside potential.

Institutional & Insider Ownership

Kodiak Sciences Inc. and Rafael Holdings Inc. has shares owned by institutional investors as follows: 48.3% and 35.2%. Insiders owned roughly 0.3% of Kodiak Sciences Inc.’s shares. Competitively, Rafael Holdings Inc. has 1.1% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kodiak Sciences Inc. 3.76% 10.6% 11.88% -10.65% 0% 8.73%
Rafael Holdings Inc. -3.82% 14.51% -0.92% 93.51% 93.74% 103.03%

For the past year Kodiak Sciences Inc.’s stock price has smaller growth than Rafael Holdings Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, focuses on the development and commercialization of oncology drugs. Rafael Holdings, Inc. is based in Newark, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.